Amedeo Smart

Free Medical Literature Service



Hepatitis C

  Free Subscription

Articles published in
    May 2024
  1. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    >> Share

  2. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    >> Share

  3. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    >> Share

  4. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    >> Share

    April 2024
  5. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    >> Share

    March 2024
  6. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    >> Share

  7. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  8. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    >> Share

    February 2024
  9. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  10. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  11. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    >> Share

    January 2024
  12. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    >> Share

  13. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    >> Share

    November 2023
  14. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    >> Share

    July 2023
  15. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    >> Share

    June 2023
  16. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    >> Share

  17. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    >> Share

    May 2023
  18. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    >> Share

    April 2023
  19. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    >> Share

  20. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    >> Share

  21. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    >> Share

    February 2023
  22. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    >> Share

    September 2022
  23. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    >> Share

    August 2022
  24. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    >> Share

  25. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    >> Share

    July 2022
  26. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.
    >> Share

  27. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.
    >> Share

  28. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    >> Share

    June 2022
  29. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    >> Share

    May 2022
    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.
    >> Share

    April 2022
  31. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    >> Share

  32. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    >> Share

    March 2022
  33. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    >> Share

  34. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.
    >> Share

  35. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    >> Share

    February 2022
  36. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
    >> Share

  37. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    >> Share

    January 2022
  38. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    >> Share

  39. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    >> Share

  40. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    >> Share

  41. JINDAL A
    Oral antivirals in treatment naive chronic hepatitis C infection.
    Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.
    >> Share

  42. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    >> Share

    December 2021
  43. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
    A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
    Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
    >> Share

  44. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
    Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
    >> Share

  45. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
    A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
    Hepatology. 2021;74:2974-2987.
    >> Share

    November 2021
  46. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    >> Share

  47. ROY A, Dhiman RK
    Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Hepatology. 2021;74:2909.
    >> Share

    October 2021
  48. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
    Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
    >> Share

  49. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    >> Share

  50. KUSHNER T, Chappell CA
    Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
    Hepatology. 2021;74:2311-2312.
    >> Share

    September 2021
  51. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
    Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
    Hepatology. 2021;74:1148-1163.
    >> Share

    August 2021
  52. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    >> Share

    July 2021
  53. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    >> Share

  54. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    >> Share

    June 2021
  55. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    >> Share

  56. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    >> Share

    May 2021
  57. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    >> Share

  58. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    >> Share

    April 2021
  59. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    >> Share

    March 2021
  60. GHANY MG, Lok ASF, Dienstag JL, Feinstone SM, et al
    The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
    Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830.
    >> Share

  61. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    >> Share

  62. JHAVERI R, Yee LM, Antala S, Murphy M, et al
    Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31825.
    >> Share

  63. GRAGNANI L, Lorini S, Marri S, Basile U, et al
    Haematological and genetic markers in the rational approach to HCV SVR patients with or without persisting cryoglobulinemic vasculitis.
    Hepatology. 2021 Mar 15. doi: 10.1002/hep.31804.
    >> Share

  64. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    >> Share

  65. COCHARD J, Bull-Maurer A, Tauber C, Burlaud-Gaillard J, et al
    Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles.
    Hepatology. 2021 Mar 4. doi: 10.1002/hep.31788.
    >> Share

    February 2021
  66. HALL EW, Schillie S, Vaughan AS, Jones J, et al
    County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756.
    >> Share

  67. ANTUORI A, Montoya V, Pineyro D, Sumoy L, et al
    Characterization of acute HCV infection and transmission networks in people who currently inject drugs in Catalonia: usefulness of dried blood spots.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31757.
    >> Share

  68. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    >> Share

  69. PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
    The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
    >> Share

  70. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.
    >> Share

    January 2021
  71. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    >> Share

    November 2020
  72. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    >> Share

  73. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    >> Share

    October 2020
  74. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    >> Share

    August 2020
  75. KAPILA N, Rahman AU, Zervos XB
    Hepatology. 2020;72:788.
    >> Share

  76. TERRAULT NA, Feld JJ
    Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R- Transplants.
    Hepatology. 2020;72:787.
    >> Share

    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    >> Share

    July 2020
  78. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    >> Share

  79. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    >> Share

    April 2020
  80. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    >> Share

    September 2019
  81. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    >> Share

    July 2019
  82. MANDORFER M, Kozbial K, Schwabl P, Chromy D, et al
    Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy.
    Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016